Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Pediatrix Misses by a Heartbeat

Pediatrix Medical Group (NYSE: PDX  ) , a health-care company focused on newborn, maternal-fetal, and other pediatric subspecialty physician services, reported a very nice increase in earnings last month. Per-share net income rose from $0.97 in last year's fourth quarter to $1.10 this year on a 10% increase in revenue.

But since the market tends to focus on negative things, the stock took a 7% hit the day of the announcement simply because earnings missed the analyst consensus projections by a penny. Sheesh. Talk about sensitive.

Still, investors have become accustomed to growth from the company. Although some of this growth was attributable to acquisitions, same-store sales (well, maybe "same-unit revenue" is a better term) popped up a respectable 4.9%, which included a rise in neonatal intensive care (NICU) admissions of 8.2%. For those of you who haven't experienced the panic that surrounds a premature or problem birth, the NICU is where your precious package gets rushed for critical care.

One interesting thing about Pediatrix is how it is managing its cash flow. During 2004, cash flow from operations was an excellent $123.8 million, almost all of which was free cash flow. The company used $65 million for acquisitions, and $150 million, comprised of cash and the company's credit line, to (can you guess?) repurchase its own shares. Now, normally I'm not wild about utilizing debt to repurchase shares. However, if management believes that the return on investment of those shares will exceed the interest rate on the debt, I'm all for it.

Investors interested in the health-care sector often look for the big names like Amgen (Nasdaq: AMGN  ) , Pfizer Inc. (NYSE: PFE  ) , and Merck & Co. (NYSE: MRK  ) . But value often comes in smaller packages. Some investors may want to examine Pediatrix more closely, just to make certain there aren't any hidden viruses waiting to sicken their portfolios. A quick glance, however, reveals a company that may be very healthy, indeed.

Fool contributor Lawrence Meyers does not own shares in any company mentioned but uses two outstanding pediatricians at private facilities.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 490880, ~/Articles/ArticleHandler.aspx, 10/24/2016 3:36:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
AMGN $158.51 Down -2.99 -1.85%
Amgen CAPS Rating: ****
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
PDX.DL2 $31.70 Down +0.00 +0.00%
Pediatrix Medical… CAPS Rating: *****
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****